Communication to Pharmacies: General
- Comunicado a Fin de Emergencia Covid -19 6.15.2023
- COM-2023-001 Summary of Puerto Rico Administrative Order 556
- ACT 142-2020 Emergency Provisional Fill Program coverage during the pre-approval process
- FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
May 2022 - COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión español
- COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión inglés
- COM-2021 – 59 Operational Guide for the submission of the transaction COVID -19 – Oral antiviral drugs emergency use
- Comunicado a Farmacias Ley -142-2020
- COM-2021-053- LEY NUM. 35 2021
- FDA Expands EUAs of Moderna’s and J&J’s COVID-19 Vaccines
November 2021 - FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
November 2021 - Prior-authorization for Ivermectin due to Increased Use during COVID-19
September 2021 - Comunicado– Carta Normativa-2021-301-D
April 2021 - COVID-19 Vaccine administration requirements
January 2021 - Billing of Insulins Pens
November 2020 - Educational bulletin of the Pharmacy Audit process
November 2020 - Final Rule Modification of the Requirements for the Use of HIPAA National Council for Prescription Drug Programs (NCPDP) D.0 Standard
October 2020 - Orden Administrativa Núm. 441 del Departamento de Salud de Puerto Rico
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine follow up after FDA’s drug safety communication
April 2020 - Carta de Clarificación- Medicamento Clopidogrel
April 2020 - Orden Administrativa Núm. 435 del Departamento de Salud de Puerto Rico
April 2020 - Recomendaciones de dispensación
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine
April 2020 - Guía operacional sobre el despacho de medicamentos durante el estado de emergencia debido al COVID-19
Marzo 2020 - Entrega de medicamentos durante el estado de emergencia debido al COVID-19 y la Ley Núm. 19-2020
Marzo 2020 - Despacho de Medicamentos en Situaciones de Emergencia y/o durante Estado de Emergencia – Poveedores Puerto Rico
Marzo 2020 - Comunicado para proveedores sobre Emergencia COVID-19
Marzo 2020 - RE: Carta Normativa ASES 19-0305. Política pública de anti-discrimen a beneficiarios por razón de identidad de género, expresión de género u orientación sexual real o percibida, al solicitar o recibir servicios de salud.
Marzo 2019 - RE: ASES Normative Letter 19-0305. Public policy for non-discrimination to beneficiaries by reason of gender identity, expression of gender or real or perceived sexual orientation, when requesting or receiving health services.
March 2019 - Guía Básica a Proveedores para manejo sensible y adecuado al brindar servicios de salud a beneficiarios LGBTT+
March 2019 - Importance of the credentialization of pharmacies – Puerto Rico
February 2019
Communication to Pharmacies: Safety
- FDA Requires Warning about Rare Itching with Cetirizine and Levocetirizine
May 2025 - FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live)
May 2025 - FDA Adds Boxed Warning for Glatiramer Acetate
January 2025 - FDA Requires GBS Warning in the Prescribing Information for Abrysvo and Arexvy
January 2025 - Serious Liver Injury in Patients Taking Ocaliva
December 2024 - Rare Occurrence of Serious Liver Injury with Use of Veozah
September 2024 - New Boxed Warning for Prolia regarding Severe Hypocalcemia
January 2024 - Evaluation of Suicidal Thoughts with Type 2 Diabetes and Obesity Drugs
January 2024
- Antiseizure Drugs Causing Rare Reaction
December 2023 - Additional Guidance Needed for Opioid Medications
MaY 2023 - Updated Warnings Required for Stimulants
May 2023 - FDA Investigating Risk of Severe Hypocalcemia with Prolia
November 2022 - FDA Warns About Possible Increased Risk of Death with Copiktra
July 2022 - FDA Requires Revisions to Warnings for JAK Inhibitors
June 2022 - FDA Investigating Possible Increased Risk of Death with Ukoniq
March 2022 - Buprenorphine Medicines and the Risk of Dental Problems
January 2022
Communication to Pharmacies: Education
- Risk of CVD Increases in Adult-Onset T1D
June 2025 - Semaglutide Shows Improvement in MASH
May 2025 - FDA Approves New UTI Antibiotic
April 2025 - FDA Approves First Novolog Biosimilar
March 2025 - Ozempic Now Approved to Lower Kidney Disease Risk in Type 2 Diabetes
February 2025 - Zepbound Approved for Obese Adults with Sleep Apnea
January 2025 - Semaglutide Improves Liver Fibrosis in New Trial Analysis
December 2024 - FDA Suggests Removing Nonprescription Decongestant from Market
November 2024
- Abrysvo FDA Approved for Adults 18 to 59 Years of Age
November 2024 - Veklury (remdesivir) for Injection by Gilead Sciences, Inc.
September 2024 - First Nasal Spray for the Treatment of Anaphylaxis
September 2024 - FDA Approves a New Alzheimer’s Disease Drug
August 2024 - First Authorized Generic for a GLP-1 Receptor Agonist
July 2024 - First Biosimilars for Eylea
June 2024 - First Therapy for WHIM Syndrome
April 2024 - New Breakthrough Indication for Wegovy
April 2024 - Dupixent Possible Approval for COPD
March 2024 - New Black Box Warning for Prolia
February 2024 - Updates Related to Drug Therapy in Diabetes Guidelines
January 2024 - Ogsiveo: The First and Only Treatment for Desmoid Tumors
December 2023 - Aliqopa Withdrawal from Market
November 2023 - Oral Phenylephrine not Effective as a Decongestant
October 2023 - FDA Approves Jardiance for Use in Chronic Kidney Disease
September 2023 - FDA Approves First Generics of ADHD and BED Treatment
August 2023 - Opill the First OTC Oral Contraceptive
July 2023 - New Class of Medications Indicated to Treat Pediatric Type 2 Diabetes
June 2023 - Opvee Nasal Spray Approved for Opioid Overdose
May 2023 - FDA Withdraws Approval of the Only Preterm Birth Medication
April 2023 - Insulin Price Reductions
March 2023 - Drugs to Watch for 2023
February 2023 - First Disease-Modifying Therapy in Type 1 Diabetes
December 2022 - Ovarian Cancer Indications Withdrawn for PARP Inhibitors
November 2022 - Biosimilars and Interchangeability
October 2022 - Monkeypox and CDC Recommendations
September 2022 - FDA Authorizes Boosters for Moderna and Pfizer Bivalent Vaccine
September 2022 - FDA Authorizes Novavax COVID-19 Vaccine in Adolescents
August 2022 - FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine
July 2022 - FDA Amends Moderna and Pfizer-BioNTech COVID-19 Vaccine’s EUAs to Include Children 6 Months of Age and Older
June 2022 - Update on Heart Failure Guidelines – A Summary
May 2022 - New Indications and First-time Generics Approved by FDA from January 2022 to March 2022
April 2022 - FDA and CDC Recommend Second Booster to Certain Individuals
March 2022 - Summary of Emergency Use Authorizations for COVID-19 Treatment
March 2022 - FDA Grants Full Approval to Moderna’s COVID-19 Vaccine
February 2022
PharmNotes
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
Recalls
- Levetiracetam in Sodium Chloride Injection
March 2025 - Fentanyl Transdermal System 25 mcg/h by Alvogen
February 2025 - Tacrolimus and Tacrolimus Extended-Release capsules by Astellas
December 2024 - Clonazepam Orally Disintegrating Tablets, USP_Endo
November 2024 - Veklury (remdesivir) for Injection by Gilead Sciences, Inc.
September 2024 - Atovaquone Oral Suspension by Bionpharma Inc.
September 2024 - Sodium Chloride 0.9%_Braun
August 2024 - Heparin Sodium_Baxter
August 2024
- Acetaminophen Injection_Hikma
July 2024 - Clonazepam ODT 0.25mg_Par Pharma
July 2024 - Potassium Chloride Extended Release 750mg Capsules, USP – American Heath on Behalf Blue Point Lab
June 2024 - Potassium Chloride Extended Release 750mg Capsule
June 2024 - Buprenorphine & Labetalol Injection
May 2024 - Docetaxel Injection
May 2024 - Sapropterin Dihydrochloride Powder for Oral Solution 100mg
April 2024 - Atovaquone Oral Suspension_AvKARE LLC
April 2024 - Methocarbamol 1000mg/10mL Injection
March 2024 - Vancomycin 250mg/5mL Oral Solution
March 2024 - Treprostinil 20mg/20mL Injection_ParPharma
March 2024 - Zenzedi 30mg Tablets
January 2024 - Bleomycin for Injection_Hospira
December 2023 - Sodium Bicarbonate and Atropine for Injection_Hospira
December 2023 - Vigabatrin Oral Solution 500mg/sachet_InvaGen
December 2023 - Sandimmune Oral Solution 100mg/mL_Novartis
November 2023 - Vitrakvi Oral Solution 20mg/mL_Bayer
November 2023 - Sodium Bicarbonate Midazolam and Elcys_Exela Pharma Sciences LLC
October 2023 - Betaxolol Tablets 10mg_KVK-Tech, Inc.
October 2023 - Brexafemme Tablets 150mg_Scynexis
October 2023 - Sucralfate Oral Suspension 1g/10mL_VistaPharm LLC
September 2023 - Sandimmune Oral Solution 100mg/mL_Novartis
September 2023 - Digoxin Tablets 0.125mg and 0.25mg_Marlex Pharmaceuticals Inc.
August 2023 - Tydemy Oral Contraceptive_Lupin Pharmaceuticals
July 2023 - Albuterol Sulfate Inhalation Aerosol_Cipla
July 2023 - Dronabinol 2.5mg and Ziprasidone 20mg_Harvard Group LLC
June 2023 - G-Supress DX Pediatric Drops 2.5mg-5mg-50mg-mL_Novis PR LLC
May 2023 - Voluntary Recall of Several Products_Akorn Operating Company
APRIL 2023 - Fentanyl Buccal Tablets_Teva Pharmaceuticals USA
April 2023 - Drug Recall :Atovaquone Oral Suspension 750mg/5mL_Camber Pharmaceuticals
April 2023 - Drug Recall : Dabigatran Etexilate Capsules 75mg and 150mg_Ascend Laboratories
March 2023 - Drug Recall: Brimonidine Tartrate Ophthalmic Solution_Apotex_032023
March 2023 - Drug Recall: Tirosint-Sol Oral Solution_IBSA Pharma Inc_022023
February 2023 - Drug Recall : Quinapril 20mg and 40mg Tablets_Lupin Pharmaceuticals_122022
December 2022 - Drug Recall : Daptomycin 500mg and 350mg Injection_122022
December 2022 - Drug Recall : Sodium Bicarbonate Injection 50mEq-50mL_Exela_112022
November 2022 - Drug Recall : Octreotide Acetate Injection_Mylan Institutional LLC_102022
October 2022 - Drug Recall : Quinapril and Hydrochlorothiazide 20mg-12.5mg_Aurobindo Pharma USA_102022
October 2022 - Drug Recall: Sodium Bicarbonate Injection Exela Pharma
October 2022 - Drug Recall: Clopidogrel 75mg and Atenolol 25mg_GSMS Inc_092022
September 2022 - Drug Recall: Acyclovir Sodium Injection_Eugia US LLC_092022
September 2022 - Drug Recall: Insulin glargine-yfgn U-100 3mL Prefilled Pens_Mylan Pharmaceuticals Inc.
July 2022 - Drug Recall: Morphine Sulfate ER 30mg and 60m Tablets_Bryant Ranch Prepack Inc.
June 2022 - Drug Recall: Accupril 10mg, 20mg and 40mg Tablets_Pfizer
April 2022 - Drug Recall: Insulin Glargine 100units/mL_Mylan Pharmaceuticals Inc., a Viatris Company
April 2022 - Drug Recall: Symjepi 0.15mg and 0.3mg_Adamis Pharmaceuticals Corp.
March 2022 - Drug Recall: Orphenadrine 100mg ER tablets_Sandoz Inc.
March 2022 - Drug Recall: Accuretic and Quinapril-Hydrochlorothiazide_Pfizer
March 2022
Join Our Network
- PharmPix Pharmacy Network Request Application
- Exception Request Form
- Important Information About Your Appeal Rights
- Concurrent Utilization Review
- Pharmacy Rights and Responsibilities
- Members Rights and Responsibilities
- Pharmacy and Therapeutics Committee
- Pricing Research Request Form
- Prior Authorization Form
- Retrospective Drug Utilization Review Program
- Universal Claim Form
- Pharmacy Credentialing/ Recredentialing
- PharmPix Pharmacy Network Provider Fraud Waste and Abuse (FWA) and General Compliance Training
- 2025 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- 2024 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- Fraud, Waste and/or Abuse Complaint Form
- PharmPix Contact Information
- Provider Complaint Form
- Pharmacy Contracting
- Pharmacy Credentialing Form
- PharmPix Provider Manual